The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...

Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...

Small-cap stocks are more important than ever. The combined forces of falling interest rates and business-friendly ...

Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ?Total ...

Stocks kept sinking up until the market close Thursday, as the major indexes finished near session lows and a postelection ...

Zyversa Therapeutics, Inc. ( (ZVSA) ) has released its Q3 earnings. Here is a breakdown of the information Zyversa Therapeutics, Inc. presented ...

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

ASX rises as MinRes falls over transparency issues, Powell dampens rate cut hopes, and NoviqTech jumps on securing blockchain ...

Inovio Pharmaceuticals ( INO -3.64%) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

Analysing Cytokinetics' potential in the biopharma market with its drug aficamten, projected peak sales of $3.6 billion and ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...